Chrysalis BioTherapeutics to Present at Respiratory Innovation Summit

GALVESTON, Texas-- Chrysalis Biotherapeutics, previously known as Chrysalis BioTechnology, has been chosen to participate in the 2024 Respiratory Innovation Summit (RIS) during the American Thoracic Society Meeting in San Diego.

The American Thoracic Society established the Respiratory Innovation Summit to bring together innovators, investors, clinicians, and advocacy groups. The goal is to foster the creation of transformative treatments for severe and debilitating respiratory diseases. Each year, organizations developing respiratory devices and therapies are invited to submit abstracts highlighting how their novel treatments could revolutionize lung disease care.

This year, Chrysalis is among six companies recognized as “Critical Care Therapeutic Innovators” and will give an oral presentation at the Summit.

"Being selected to present at the Respiratory Summit is a significant honor for Chrysalis and underscores the recognition of TP508 (Chrysalin™) by industry experts for its potential to halt the progression of acute lung injury," stated Dr. Darrell Carney, CEO of Chrysalis.

Chrysalis is advancing TP508, a peptide derived from natural thrombin, aimed at treating Acute Respiratory Distress Syndrome (ARDS). This condition impacts over a million individuals annually, with up to 35% succumbing within weeks after diagnosis. Survivors often face diminished lung function or ongoing fibrosis.

"Based on preclinical outcomes from COVID and acute lung injury models, we anticipate that TP508 will prevent the progression of ARDS," remarked Dr. Laurie Sower, Executive Vice President of Chrysalis.

Chrysalis has obtained FDA IND approval to move forward with human clinical trials, launching a Phase 1 Safety/PK trial. Further trials involving ARDS patients will commence as the company secures the necessary funding.

Chrysalis BioTherapeutics, Inc., a private biopharmaceutical company headquartered in Galveston, TX, holds a global license for TP508 technology from the University of Texas System and the University of Texas Medical Branch (UTMB). The company is actively seeking investors and pharmaceutical partners for pulmonary and other applications, including traumatic brain injury (TBI), radiation therapy, and the treatment of chronic pulmonary diseases. Chrysalis’s drug development projects, particularly Chrysalin™, have received funding from the NIH and the Biomedical Advanced Research and Development Authority (BARDA), both entities under the U.S. Department of Health and Human Services.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!